[1]朱婷婷,黄丹,张春元,等.玻璃体内注射康柏西普对糖尿病黄斑水肿患者和继发于视网膜静脉阻塞的黄斑水肿患者的疗效差异[J].眼科新进展,2023,43(1):053-56.[doi:10.13389/j.cnki.rao.2023.0011]
　ZHU Tingting,HUANG Dan,ZHANG Chunyuan,et al.Different efficacies of intravitreal injection of conbercept for diabetic macular edema and macular edema secondary to retinal vein obstruction[J].Recent Advances in Ophthalmology,2023,43(1):053-56.[doi:10.13389/j.cnki.rao.2023.0011]
点击复制

玻璃体内注射康柏西普对糖尿病黄斑水肿患者和继发于视网膜静脉阻塞的黄斑水肿患者的疗效差异/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年1期
页码:
053-56
栏目:
应用研究
出版日期:
2023-01-05

文章信息/Info

Title:
Different efficacies of intravitreal injection of conbercept for diabetic macular edema and macular edema secondary to retinal vein obstruction
作者:
朱婷婷; 黄丹; 张春元; 孙瑞竹; 刘振兴; 顾喆瑶; 马戈; 奚婷
215008　江苏省苏州市，南京医科大学姑苏学院，苏州市立医院，南京医科大学附属苏州医院眼科
Author(s):
ZHU Tingting; HUANG Dan; ZHANG Chunyuan; SUN Ruizhu; LIU Zhenxing; GU Zheyao; MA Ge; XI Ting
Department of Ophthalmology,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School of Nanjing Medical Univercity,Suzhou 215008,Jiangsu Province,China
关键词:
血管内皮生长因子; 糖尿病视网膜病变; 视网膜静脉阻塞; 康柏西普; 黄斑水肿
Keywords:
vascular endothelial growth factor;  diabetic retinopathy;  retinal vein obstruction;  conbercept;  macular edema
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2023.0011
文献标志码:
A
摘要:
目的　探讨玻璃体内注射康柏西普对糖尿病黄斑水肿（DME）患者和继发于视网膜静脉阻塞（RVO）的黄斑水肿患者的疗效差异。
方法　回顾性研究。选取2019年8月至2021年12月在苏州市立医院北区眼科行玻璃体内注射康柏西普治疗的DME患者44例63眼记为DME组，另选取采用同样方法进行治疗的继发于RVO的黄斑水肿患者40例40眼记为RVO组。采用国际标准视力表（小数）检查并记录患者最佳矫正视力（BCVA），采用德国海德堡公司OCT仪进行OCT检查，自动测量患者黄斑中心凹1 mm视网膜厚度并以此作为黄斑中心视网膜厚度（CMT）。所有患者玻璃体内均一次性注射0.05 mL康柏西普（成都康弘生物科技有限公司）。对比分析DME组和RVO组患眼基线特征及康柏西普治疗后7 d疗效差异。
结果　DME组患眼基线 CMT为（484.94±152.89）μm，RVO组为（582.33±241.57）μm，RVO组基线CMT高于DME组，差异有统计学意义（P<0.05）。DME组患眼基线BCVA为0.31±0.20，RVO组为0.29±0.23，差异无统计学意义（P>0.05）。注射后7 d，DME组患眼CMT为（333.40±88.08）μm，较基线CMT改变量为（-151.54±118.24）μm，注射前后差异有统计学意义（t=10.173，P<0.01）；注射后7 d，DME组患眼BCVA为0.59±0.23，较基线BCVA改变量为0.28±0.18，注射前后差异有统计学意义（t=-12.609,P<0.01）。注射后7 d，RVO组患眼CMT为（306.03±82.64）μm，较基线CMT改变量为（-276.30±214.88）μm，注射前后差异有统计学意义（t=8.132，P<0.01）；注射后7 d，RVO组患眼BCVA为0.74±0.27，较基线BCVA改变量为0.45±0.21，注射前后差异有统计学意义（t=-13.258,P<0.01）。注射后7 d，RVO组患眼CMT减少量和BCVA提高量均高于DME组，差异均有统计学意义（均为P<0.05）。
结论　玻璃体内注射康柏西普治疗DME和继发于RVO的黄斑水肿在患者水肿消退及视力提高方面疗效均显著，继发于RVO的黄斑水肿患者经康柏西普治疗后疗效较DME患者更好。
Abstract:
Objective　To compare the different efficacies of intravitreal injection of conbercept (IVC) on patients with diabetic macular edema (DME) and patients with macular edema (ME) secondary to retinal vein obstruction (RVO).
Methods　In this retrospective study, patients who were treated with IVC from August 2019 to December 2021 in the Ophthalmology Department of Suzhou Municipal Hospital North Campus were included, among which 44 patients (63 eyes) with DME were divided into the DME group, and 40 patients (40 eyes) with ME secondary to RVO were divided into the RVO group. The international standard visual acuity chart (decimal) was used to check and record the best corrected visual acuity (BCVA) of the patients. The optical coherence tomography (OCT) instrument of Heidelberg Instruments was used to automatically measure the average retinal thickness of the macular fovea in the central 1 mm area as the central macular thickness (CMT). Conbercept (Chengdu Kanghong Biotechnology Co., Ltd.) was administered intravitreally to all patients at a dose of 0.05 mL. The baseline characteristics and IVC efficacies in the DME group and RVO group were compared.
Results　The baseline CMT was (484.94±152.89)μm in the DME group and (582.33±241.57)μm in the RVO group, and the baseline CMT in the RVO group was significantly higher than that in the DME group (P<0.05). The baseline BCVA in the DME group was 0.31±0.20, and that in the RVO group was 0.29±0.23, with no statistically significant difference (P>0.05). At 7 d after the injection, the CMT in the DME group was (333.40±88.08)μm, changing by (-151.54±118.24) μm, with a statistically significant difference (t=10.173, P<0.01); the BCVA in the DME group was 0.59±0.23, changing by 0.28±0.18, with a statistically significant difference (t=-12.609, P<0.01). At 7d after the injection, the CMT in the RVO group was (306.03±82.64)μm, changing by (-276.30±214.88)μm, with a statistically significant difference (t=8.132, P<0.01); the BCVA was 0.74±0.27, changing by 0.45±0.21, with a statistically significant difference (t=-13.258, P<0.01). The RVO group had a better reduction of CMT and a greater improvement in BCVA than the DME group after 7 d IVC therapy (both P<0.05).
Conclusion　IVC therapy is effective for detumescence and vision improvement in treating both DME and ME secondary to RVO. After IVC therapy, patients with ME secondary to RVO have more improvement than those with DME.

参考文献/References:

［1］　KLEIN R,KNUDTSON M D,LEE K E,GANGNON R,KLEIN B E.The Wisconsin epidemiologic study of diabetic retinopathy:XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes［J］.Ophthalmology,2008,115(11):1859-1868.
［2］　LANG G E,LANG S J.Clinical treatment of diabetic macular edema［J］.Klin Monbl Augenheilkd,2011,228(1)：R1-11.
［3］　Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema［J］.Arch Ophthalmol,1985,103(12):1796-1806.
［4］　HAYREH S S.Ocular vascular occlusive disorders:natural history of visual outcome［J］.Prog Retin Eye Res,2014,41:1-25.
［5］　WELLS J A,GLASSMAN A R,JAMPOL L M,AIELLO L P,ANTOSZYK A N,BAKER C W,et al.Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept,bevacizumab,and ranibizumab for diabetic macular edema［J］.JAMA Ophthalmol,2016,134(2):127-134.
［6］　XU Y,RONG A,XU W,NIU Y,WANG Z.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study［J］.BMC Ophthalmol,2017,17(1):158.
［7］　LI F,ZHANG L,WANG Y,XU W,JIAO W,MA A,et al.One-year outcome of conbercept therapy for diabetic macular edema［J］.Curr Eye Res,2018,43(2):218-223.
［8］　BOYER D,HEIER J,BROWN D M,CLARK W L,VITTI R,BERLINER A J,et al.Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion:six-month results of the phase 3 COPERNICUS study［J］.Ophthalmology,2012,119(5):1024-1032.
［9］　HEIER J S,CLARK W L,BOYER D S,BROWN D M,VITTI R,BERLINER A J,et al.Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion:two-year results from the COPERNICUS study［J］.Ophthalmology,2014,121(7):1414-1420.
［10］　NGUYEN Q D,BROWN D M,MARCUS D M,BOYER D S,PATEL S,FEINER L,et al.RISE and RIDE Research Group.Ranibizumab for diabetic macular edema:results from 2 phase III randomized trials:RISE and RIDE［J］.Ophthalmology,2012,119(4):789-801.
［11］　BROWN D M,NGUYEN Q D,MARCUS D M,BOYER D S,PATEL S,FEINER L,et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema:the 36-month results from two phase III trials:RISE and RIDE［J］.Ophthalmology,2013,120(10):2013-2022.
［12］　HEIER J S,KOROBELNIK J F,BROWN D M,SCHMIDT-ERFURTH U,DO D V,MIDENA E,et al.Intravitreal aflibercept for diabetic macular edema:148-week results from the VISTA and VIVID studies［J］.Ophthalmology,2016,123(11):2376-2385.
［13］　SCHMIDT-ERFURTH U,LANG G E,HOLZ F G,SCHLINGEMANN R O,LANZETTA P,MASSIN P,et al.Three-year out comes of individualized ranibizumab treatment in patients with diabetic macular edema：the RESTORE extension study［J］.Ophthalmology,2014,121(5):1045-1053.
［14］　ZARBIN M A,DUNGER-BALDAUF C,HASKOVA Z,KOOVEJEE P,MOUSSEAU M C,MARGARON P,et al.Vascular safety of ranibizumab in patients with diabetic macular edema:a pooled analysis of patient-level data from randomized clinical trials［J］.JAMA Ophthalmol,2017,135(5):424-431.
［15］　VIRGILI G,PARRAVANO M,EVANS J R,GORDON I,LUCENTEFORTE E.Anti-vascular endothelial growth factor for diabetic macular oedema:a network meta-analysis［J］.Cochrane Database Syst Rev,2017,6(6):CD007419.
［16］　ZHANG X,BAO S,LAI D,RAPKINS R W,GILLIES M C.Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas［J］.Diabetes,2008,57(4):1026-1033.
［17］　LIU K C,DAGLI M.Arcuate retinal nerve fiber layer defect after laser photocoagulation for diabetic macular edema［J］.JAMA Ophthalmol,2017,135(12):e174877.
［18］　TABABAT-KHANI P,BENGTSSON B,AGARDH E.Effects of focal/grid laser treatment on the central visual field in diabetic macular oedema:a 2-year follow-up study［J］.Acta Ophthalmol,2016,94(3):240-245.
［19］　OLK R J.Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema［J］.Ophthalmology,1986,93:938-950.
［20］　SUZUKI Y,NAKAZAWA M,SUZUKI K,YAMAZAKI H,MIYAGAWA Y.Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion［J］.Jpn J Ophthalmol,2011,55(3):256-263
［21］　NOMA H,FUNATSU H,YAMASAKI M,TSUKAMOTO H,MIMURA T,SONE T,et al.Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6［J］.Am J Ophthalmol,2005,140(2):256-261.
［22］　AIELLO L.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders［J］.N Engl J Med,1994,331(22):1480-1487.
［23］　TARALLO V,DE FALCO S.The vascular endothelial growth factors and receptors family;Up to now the only target for anti-angiogenesis therapy［J］.Int J Biochem Cell Biol,2015,64:185-189.
［24］　LASHAY A,RIAZI-ESFAHANI H,MIRGHORBANI M,YASERI M.Intravitreal medications for retinal vein occlusion:systematic review and meta-analysis［J］.J Ophthalmic Vis Res,2019,14(3):336-366.
［25］　蒋莉，李劲，聂爱芹.玻璃体内注射康柏西普治疗糖尿病黄斑水肿的疗效观察［J］.国际眼科杂志，2017，17（6）：1105-1107
JIANG L,LI J,NIE A Q.Clinical observation of intravitreal injection of Conbercept treating diabetic macular edema［J］.Int Eye Sci,2017,17(6）：1105-1107.
［26］　LI F,SUN M,GUO J,MA A,ZHAO B.Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion［J］.Curr Eye Res,2017,42(8):1174-1178.
［27］　XU Y,RONG A,XU W,NIU Y,WANG Z.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study［J］.BMC Ophthalmol,2017,17(1):158.
［28］　BROWN D M,HEIER J S,CLARK W L,BOYER D S,VITTI R,BERLINER A J,et al.Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion:1-year results from the phase 3 COPERNICUS study［J］.Am J Ophthalmol,2013,155(3):429-437.

相似文献/References:

[1]程文武 江萍 席祖莲 张汉武 訾世莉 聂军 董彩虹.蛹虫草提取物抑制大鼠角膜新生血管的实验研究[J].眼科新进展,2012,32(5):000.
[2]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[3]于静 张明昌.苦参碱对大鼠角膜新生血管的抑制作用[J].眼科新进展,2012,32(6):000.
[4]吴正正 严京 接传红 高健生 陈皆春 宋剑涛.密蒙花方对缺氧状态下脐静脉血管内皮细胞 VEGF-VEGFR 信号转导通路的影响[J].眼科新进展,2012,32(7):000.
[5]庞霞 曲蕴慧 马跃伟 张效房 董敬民 高冬玲.去整合素金属蛋白酶9和血管内皮生长因子蛋白在眼部恶性黑色素瘤中的表达[J].眼科新进展,2012,32(7):000.
[6]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[7]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[8]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[9]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[10]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[11]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[12]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[13]曾莉 常以力 邵毅.血管内皮生长因子反义寡脱氧核苷酸联合血管生成素-1对糖尿病视网膜病变大鼠视网膜血管渗漏及新生血管生成的影响[J].眼科新进展,2012,32(10):000.
[14]兰兰 惠延年 曾光伟.血管生成素-1对糖尿病大鼠视网膜微血管病变、基质金属蛋白酶和血管内皮生长因子的抑制作用[J].眼科新进展,2012,32(10):000.
[15]谢明捷 吕红彬 何跃 赵春会.炎症因子与糖尿病视网膜病变相关性研究进展[J].眼科新进展,2012,32(10):000.
[16]邵敬芝 彭广华.VEGF基因多态性与糖尿病视网膜病变相关性的研究进展[J].眼科新进展,2013,33(9):000.
[17]王清 郭乔茜 李琴 谢婷玉 陈雪艺. 臭氧治疗对糖尿病大鼠视网膜细胞凋亡和VEGF、PEDF因子表达的影响[J].眼科新进展,2014,34(3):232.
[18]王坤,万光明,徐亚娟,等.糖尿病合并高度近视患者玻璃体中VEGF和EPO的表达及意义[J].眼科新进展,2014,34(5):445.[doi:10.13389/j.cnki.rao.2014.0121]
　WANG Kun,WAN Guang-Ming,XU Ya-Juan,et al.Expression and significance of VEGF and EPO in vitreous body of diabetes mellitus with high myopia[J].Recent Advances in Ophthalmology,2014,34(1):445.[doi:10.13389/j.cnki.rao.2014.0121]
[19]武淑玲,杨默迟,袁进萍. PDR患者血浆、眼内组织纤溶酶原激活物及其抑制剂与VEGF的表达及相关性[J].眼科新进展,2014,34(7):647.[doi:10.13389/j.cnki.rao.2014.0177]
[20]郭露,吕红彬. VEGF基因多态性与糖尿病视网膜病变的关系[J].眼科新进展,2015,35(4):397.[doi:10.13389/j.cnki.rao.2015.0108]
　GUO Lu,LV Hong-Bin. Correlation between VEGF gene polymorphism and diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(1):397.[doi:10.13389/j.cnki.rao.2015.0108]

备注/Memo

备注/Memo:
南京医科大学科技发展基金项目(编号：NMUB20210275)
更新日期/Last Update: 2023-01-05